Posts by tag
2HR-positive/ HER2-negative breast cancer
1 post
Adding a CDK4/6 inhibitor to endocrine therapy improves outcomes in HR+ HER2– early-stage breast cancer
Adding the CDK4/6 inhibitor ribociclib to standard-of-care adjuvant endocrine therapy for treatment of hormone receptor-positive HER2-negative early-stage breast cancer reduced risk of recurrence by 25%. The phase III NATALEE study, abstract LBA500, presented at the ASCO 2023 Annual Meeting, held…